ASKB589
First-Line Advanced Gastric and Gastroesophageal Junction Cancers
Key Facts
About Askgene Pharma
AskGene Pharma is a private, clinical-stage biotech leveraging its proprietary SmartKine platform to create cytokine prodrugs with improved safety and efficacy. The company's lead asset, ASKB589, is an anti-CLDN18.2 antibody currently in a pivotal Phase 3 trial for first-line advanced gastric/gastroesophageal junction cancers, demonstrating significant clinical progress. Led by a team of seasoned industry veterans from companies like Genentech and Amgen, AskGene is positioned to tackle the historical challenges of cytokine therapy, primarily peripheral toxicity and short half-life. The company operates in high-value therapeutic areas with substantial unmet needs but faces typical biotech risks related to clinical trial outcomes, platform validation, and funding.
View full company profile